SCHEMBL20090112

SCHEMBL20090112

S=P(c1ccc(-c2ccc3c(ccc4c5ccccc5c5nc6ccccc6n5c34)c2)nc1)(c1cc2ccccc2c2ccccc12)c1cc2ccccc2c2ccccc12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.34
ALDH1A1 P00352 4/20 0.34
KDM4E B2RXH2 4/20 0.34
KMT2A Q03164 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPT P10636 2/20 0.32
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
POLB P06746 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TUBB4A P04350 1/20 0.32
TUBB P07437 1/20 0.32
TUBA3C P0DPH7 1/20 0.32
TUBA1B P68363 1/20 0.32
TUBA4A P68366 1/20 0.32
TUBB4B P68371 1/20 0.32
TUBB3 Q13509 1/20 0.32
TUBB2A Q13885 1/20 0.32
TUBB8 Q3ZCM7 1/20 0.32
TUBA3E Q6PEY2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20090089 0.96 HPGD (0.35) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL20096624 0.95 TUBB4A (0.32) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL20090133 0.95 ALDH1A1 (0.32) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL20090106 0.91 HPGD (0.34) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL20090222 0.91 HPGD (0.39) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL20090084 0.88 HPGD (0.34) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL20090120 0.88 ALDH1A1 (0.32) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL20090098 0.85 KDM4E (0.32) HPGDALDH1A1KDM4EMAPTLMNA
SCHEMBL19960322 0.85 CYP11B1 (0.32) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL20090076 0.84 HPGD (0.38) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10355225-B2 Heterocyclic compound and organic light emitting element comprising same LG CHEM, LTD. (KR) 2019-07-16 US disclosed
US-20180114923-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME LG CHEM, LTD. (KR) 2018-04-26 US disclosed
US-20180114923-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME LG CHEM, LTD. (KR) 2018-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180114923-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME CRY1, CRY2, PER2 HPGD 2982/4885ALDH1A1 750/4885KDM4E 1997/4885
US-10355225-B2 Heterocyclic compound and organic light emitting element comprising same CRY1, CRY2, PER2 HPGD 2982/4885ALDH1A1 750/4885KDM4E 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.